Palonosetron (PALO) plus aprepitant (APREP) and dexamethasone (DEX) for the prevention of chemotherapy-induced nausea and vomiting (CINV) after emetogenic chemotherapy (CT)

被引：0
|
作者：
Grote, T
Hajdenberg, J
Cartmell, A
Ferguson, S
Ginkel, A
Gallagher, S
Charu, V
机构：
[1] Piedmont Hematol Oncol, Winston Salem, NC USA
[2] Pasco Pinellas Canc Ctr, Tarpon Springs, FL USA
[3] Comprehens Blood & Canc Inst, Bakersfield, CA USA
[4] Cooper Green Hosp, Birmingham, AL USA
[5] MGI Pharma, Bloomington, MN USA
[6] Pacific Canc Med Ctr, Anaheim, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8262
引用
下载
收藏
页码：794S / 794S
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF TRIPLET ANTIEMETIC THERAPY FOR CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN LUNG CANCER PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY: PALONOSETRON, APREPITANT, AND DEXAMETHASONE
    Hayashi, M.
    Miura, S.
    Sato, K.
    Makino, M.
    Kobayashi, O.
    Miyao, H.
    Iwashima, A.
    Ichikawa, K.
    Koshio, J.
    Watanabe, S.
    Tanaka, J.
    Kagamu, H.
    Yokoyama, A.
    Narita, I.
    Yoshizawa, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 88 - 88
  • [22] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
  • [23] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
    Aapro, Matti S.
    Rossi, Giorgia
    Rizzi, Giada
    Palmas, Marco
    Grunberg, Steven
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] COST-EFFECTIVENESS OF PALONOSETRON FOR THE PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING ASSOCIATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY
    Rely, K.
    Pierre, K. A.
    Salinas, E. G.
    VALUE IN HEALTH, 2009, 12 (07) : A496 - A496
  • [25] Cost-effectiveness of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with highly emetogenic chemotherapy
    Moore, Susan
    Tumeh, John
    Wojtanowski, Steven
    Flowers, Christopher
    VALUE IN HEALTH, 2007, 10 (01) : 23 - 31
  • [26] Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy
    Warr, DG
    Hesketh, PJ
    Gralla, RJ
    Muss, HB
    Herrstedt, J
    Eisenberg, PD
    Raftopoulos, H
    Grunberg, SM
    Gabriel, M
    Rodgers, A
    Bohidar, N
    Klinger, G
    Hustad, CM
    Horgan, KJ
    Skobieranda, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (12) : 2822 - 2830
  • [27] Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers
    Gralla, R.
    Rapoport, B.
    Brown, C.
    Street, J. C.
    Hardwick, J. S.
    Carides, A. D.
    EJC SUPPLEMENTS, 2009, 7 (03): : 23 - 24
  • [28] Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer
    Joseph S. Bubalo
    Jon D. Herrington
    Marc Takemoto
    Patricia Willman
    Michael S. Edwards
    Casey Williams
    Alan Fisher
    Alison Palumbo
    Eric Chen
    Charles Blanke
    Charles D. Lopez
    Supportive Care in Cancer, 2018, 26 : 1273 - 1279
  • [29] Palonosetron and netupitant for prevention of chemotherapy-induced nausea and vomiting
    De Lartigue, Jane
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2015, 13 (04): : 128 - 130
  • [30] Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting
    Ruhlmann, Christina
    Herrstedt, Jorn
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (02) : 137 - 148
12345